Core Viewpoint - Xianweida Biotech has received approval from the National Medical Products Administration (NMPA) for its drug, Enogratide injection, aimed at blood sugar control in adults with type 2 diabetes, marking a significant advancement in diabetes treatment in China [1][2] Company Summary - Xianweida Biotech's Enogratide injection is a cAMP biased GLP-1 receptor agonist, differing from non-biased GLP-1 receptor agonists by preferentially activating the cAMP signaling pathway while minimizing β-arrestin recruitment, which helps maintain receptor presence on the cell surface and enhances therapeutic signaling [1][2] - The approval is seen as a milestone for Chinese pharmaceutical companies in the metabolic disease sector, with the company aiming to leverage this achievement to further innovate and provide transformative therapies for diabetes management [2] Industry Summary - The number of diabetes patients in China is projected to reach approximately 148 million by 2024, with evolving treatment goals that now include not only blood sugar control but also cardiovascular risk reduction and organ function protection [1] - GLP-1 receptor agonists are recognized as core therapeutic agents for adult type 2 diabetes, with the latest guidelines acknowledging the importance of precision treatment approaches [1]